Metagenomi Therapeutics, Inc. (MGX) Fair Value 2026

MGX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Metagenomi Therapeutics, Inc. (MGX) trades at $1.19, versus a $2.31 median fair value across its 2 active models — 94.3% above the current price. QOC: 5.7/10. Value Trap Risk: 42/100 (WARN). 2/13 models active.

Key Facts

Ticker
MGX
Price
$1.19
Quality Score
5.7/10
Value Trap Risk
42/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +229.4% upside with 27% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is Metagenomi Therapeutics, Inc. (MGX) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Metagenomi Therapeutics, Inc. (MGX) appears undervalued as of : the median of 2 independent fair value estimates is $2.31, 94.3% above the current price of $1.19. Estimates range from $0.71 to $3.92. MGX scores 5.7/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. MGX’s +94.3% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Metagenomi Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give MGX?

2 Intrinsic Value Models vs. Current Price ($1.19)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.71 -40.7%
Option-Based · Medium Conviction
 $3.92 +229.4%

All Models Active

All 2 models are displayed above.

What Is Metagenomi Therapeutics, Inc. (MGX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Metagenomi Therapeutics, Inc. presents a highly debated valuation profile at its current price of $1.19. The median intrinsic value is estimated at $2.31 (+94.3% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: PWERM targets $3.92 (+229.4%), versus ML-RIV at $0.71 (-40.7%). This +270.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About MGX?

2 of 13 models are currently active for MGX. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for MGX is $2.31 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does MGX Rank in Biotechnology?

Among 625 Biotechnology stocks, MGX ranks #185 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Metagenomi Therapeutics, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is MGX a Value Trap?

CirclFi's Value Trap algorithm assigns MGX a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Metagenomi Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Metagenomi Therapeutics, Inc. scores 5.7 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +270.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MGX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MGX's 2 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Metagenomi Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NRXSNeurAxis, Inc.QOC 5.7LITSLite Strategy, Inc.QOC 5.7TRDAEntrada Therapeutics, Inc.QOC 5.7ENTXEntera Bio Ltd.QOC 5.7SXTP60 Degrees Pharmaceuticals, Inc.QOC 5.7OTLCOncotelic Therapeutics, Inc.QOC 5.7EMMAEmmaus Life Sciences, Inc.QOC 4.9DCOYDecoy Therapeutics Inc.QOC 4.3VXRTVaxart, Inc.QOC 8.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NRXS · LITS · TRDA · ENTX · SXTP · OTLC · EMMA · DCOY · VXRT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MGX?

5 companies across all industries closest to MGX’s Quality of Company score of 5.7/10.

SRLScully Royalty Ltd.QOC 5.7VEEAVeea Inc.QOC 5.7BKDBrookdale Senior Living Inc.QOC 5.7TLSITriSalus Life Sciences, Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SRL · VEEA · BKD · TLSI · NVDA

Where Does MGX Sit in CirclFi's Biotechnology Rankings?

MGX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Metagenomi Therapeutics, Inc.’s Valuation?

What is Metagenomi Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Metagenomi Therapeutics, Inc. (MGX)'s intrinsic value at $2.31 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.71 to $3.92. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MGX overvalued or undervalued right now?

At $1.19, 1 of 2 active models suggest MGX may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $2.31, 94.3% above the current price of $1.19 — a consensus view that MGX is undervalued. The assessment depends on which methodology best fits Metagenomi Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for MGX?

Metagenomi Therapeutics, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MGX?

CirclFi analyzes MGX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is MGX a value trap in 2026?

Metagenomi Therapeutics, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Metagenomi Therapeutics, Inc. (MGX) has a median fair value of $2.31 — 94.3% above the current price of $1.19 — as of 2026-08-28.” Source: circlfi.com/stock/MGX/ · Methodology
Primary sources for this MGX valuation
  • Financial statements: Metagenomi Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001785279) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MGX as of ; valuations recomputed .